Tower Research Capital LLC TRC Grows Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

Tower Research Capital LLC TRC grew its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 252.3% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,615 shares of the company’s stock after purchasing an additional 2,589 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Zentalis Pharmaceuticals were worth $55,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ZNTL. Vanguard Group Inc. lifted its stake in shares of Zentalis Pharmaceuticals by 6.2% during the 3rd quarter. Vanguard Group Inc. now owns 5,236,663 shares of the company’s stock worth $105,047,000 after purchasing an additional 307,490 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Zentalis Pharmaceuticals by 8.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,064 shares of the company’s stock worth $8,868,000 after buying an additional 36,219 shares during the last quarter. SG Americas Securities LLC grew its holdings in Zentalis Pharmaceuticals by 4.3% in the 4th quarter. SG Americas Securities LLC now owns 152,747 shares of the company’s stock valued at $2,314,000 after buying an additional 6,252 shares during the period. Bank of New York Mellon Corp increased its stake in shares of Zentalis Pharmaceuticals by 47.1% during the 3rd quarter. Bank of New York Mellon Corp now owns 242,109 shares of the company’s stock valued at $4,857,000 after acquiring an additional 77,572 shares during the last quarter. Finally, TD Asset Management Inc lifted its holdings in shares of Zentalis Pharmaceuticals by 76.1% during the 3rd quarter. TD Asset Management Inc now owns 180,768 shares of the company’s stock worth $3,626,000 after acquiring an additional 78,140 shares during the period.

Insider Buying and Selling

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $11.44, for a total transaction of $29,435.12. Following the sale, the chief financial officer now directly owns 451,449 shares in the company, valued at approximately $5,164,576.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ZNTL shares. HC Wainwright restated a “buy” rating and issued a $46.00 target price on shares of Zentalis Pharmaceuticals in a report on Wednesday, February 28th. Wedbush boosted their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.57.

Zentalis Pharmaceuticals Price Performance

NASDAQ ZNTL traded up $0.36 during trading hours on Monday, hitting $11.42. The company had a trading volume of 514,305 shares, compared to its average volume of 793,302. The firm’s 50 day moving average is $14.05 and its 200 day moving average is $13.72. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $9.56 and a fifty-two week high of $31.46. The company has a market capitalization of $810.36 million, a price-to-earnings ratio of -2.52 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.09. On average, equities analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.